Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
ASTH Quote, Financials, Valuation and Earnings
Last price:
$24.2500
Seasonality move
:
8.69%
Day range:
$22.9900 - $24.1900
52-week range:
$18.0800 - $34.8000
Dividend yield:
0%
P/E ratio:
53.19x
P/S ratio:
0.38x
P/B ratio:
1.52x
Volume:
499.9K
Avg. volume:
590.6K
1-year change:
-21.61%
Market cap:
$1.2B
Revenue:
$3.2B
EPS (TTM):
$0.46
Analysts' Opinion
-
Consensus RatingAstrana Health, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $36.0000, Astrana Health, Inc. has an estimated upside of 48.39% from its current price of $24.1900.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.0000 representing -7.17% downside risk from its current price of $24.1900.
Fair Value
-
According to the consensus of 10 analysts, Astrana Health, Inc. has 48.39% upside to fair value with a price target of $36.0000 per share.
ASTH vs. S&P 500
-
Over the past 5 trading days, Astrana Health, Inc. has underperformed the S&P 500 by -3.12% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Astrana Health, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Astrana Health, Inc. has grown year-over-year revenues for 20 quarters straight. In the most recent quarter Astrana Health, Inc. reported revenues of $950.5M.
Earnings Growth
-
Astrana Health, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Astrana Health, Inc. reported earnings per share of $0.12.
Enterprise value:
1.6B
EV / Invested capital:
0.99x
Price / LTM sales:
0.38x
EV / EBIT:
20.55x
EV / Revenue:
0.51x
PEG ratio (5yr expected):
0.78x
EV / Free cash flow:
15.44x
Price / Operating cash flow:
11.45x
Enterprise value / EBITDA:
12.98x
Gross Profit (TTM):
$295.8M
Return On Assets:
1.4%
Net Income Margin (TTM):
0.76%
Return On Equity:
4.49%
Return On Invested Capital:
1.94%
Operating Margin:
1.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $1.4B | $2B | $3.2B | $665.2M | $950.5M | |
| Gross Profit | $197.2M | $243.5M | $295.8M | $42.4M | $78.6M | |
| Operating Income | $84.6M | $89.4M | $78.5M | $720K | $18.4M | |
| EBITDA | $102.4M | $117.3M | $124.3M | $8.8M | $34.8M | |
| Diluted EPS | $1.29 | $0.90 | $0.46 | -$0.15 | $0.12 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $404.5M | $428.1M | $461.5M | $638.5M | $863.3M | |
| Total Assets | $886.5M | $989.9M | $955.5M | $1.4B | $2.2B | |
| Current Liabilities | $114.7M | $148.6M | $218.7M | $365.6M | $615.3M | |
| Total Liabilities | $375.8M | $431.4M | $544.7M | $861.4M | $1.7B | |
| Total Equity | $510.6M | $558.5M | $410.8M | $514.2M | $558.3M | |
| Total Debt | $198.4M | $225.8M | $316.4M | $466.5M | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $68.2M | $52.2M | $114.6M | -$10.9M | -$2.9M | |
| Cash From Investing | -$65.6M | -$192.3M | -$539M | -$33.3M | -$1.1M | |
| Cash From Financing | $3.5M | $135M | $569.3M | -$15.3M | -$26.3M | |
| Free Cash Flow | $39.7M | $44.2M | $104.5M | -$13.5M | -$6M | |
ASTH
Sector
Market Cap
$1.2B
$25.1M
Price % of 52-Week High
69.71%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
-8.66%
-1.6%
1-Year Price Total Return
-16.9%
-18.38%
Beta (5-Year)
0.911
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$24.8438
200-day SMA
Sell
Level
$25.8292
Bollinger Bands (100)
Sell
Level
20.528 - 29.088
Chaikin Money Flow
Sell
Level
-3M
20-day SMA
Buy
Level
$21.6625
Relative Strength Index (RSI14)
Buy
Level
55.6548
ADX Line
Buy
Level
27.5384
Williams %R
Neutral
Level
-30.6621
50-day SMA
Buy
Level
$23.5958
MACD (12, 26)
Buy
Level
0.6355
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
31.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3179)
Buy
CA Score
(Annual)
Level (0.0382)
Sell
Beneish M-Score
(Annual)
Level (-1.6711)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.1541)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Astrana Health, Inc. is a physician-centric, technology-powered, risk-bearing healthcare management company. It operates as an integrated healthcare delivery platform, providing services like Primary Care, Multi-Specialty Care, Immediate Care, Radiology, and Laboratory. The company was founded by Kenneth Sin and Thomas S. Lam in 1985 and is headquartered in Alhambra, CA.
Stock Forecast FAQ
In the current month, ASTH has received 8 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ASTH average analyst price target in the past 3 months is $36.0000.
-
Where Will Astrana Health, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Astrana Health, Inc. share price will rise to $36.0000 per share over the next 12 months.
-
What Do Analysts Say About Astrana Health, Inc.?
Analysts are divided on their view about Astrana Health, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Astrana Health, Inc. is a Sell and believe this share price will drop from its current level to $26.0000.
-
What Is Astrana Health, Inc.'s Price Target?
The price target for Astrana Health, Inc. over the next 1-year time period is forecast to be $36.0000 according to 10 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ASTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Astrana Health, Inc. is a Buy. 8 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ASTH?
You can purchase shares of Astrana Health, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Astrana Health, Inc. shares.
-
What Is The Astrana Health, Inc. Share Price Today?
Astrana Health, Inc. was last trading at $24.2500 per share. This represents the most recent stock quote for Astrana Health, Inc.. Yesterday, Astrana Health, Inc. closed at $24.1900 per share.
-
How To Buy Astrana Health, Inc. Stock Online?
In order to purchase Astrana Health, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ASTH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ASTH
Sector
P/E ratio
53.19x
21.37x
PEG ratio
0.78x
-0.01x
P/B ratio
1.52x
1.73x
Price / LTM sales
0.38x
1.46x
Growth Metrics
ASTH
Sector
Revenue growth
42.89%
3.27%
Earnings growth
183.52%
12.13%
Revenue (5-year growth)
35.87%
6.25%
Earnings forecast
$0.33
-$0.20
Profitability
ASTH
Sector
Profitability FY 2025
$295.8M
$2.3M
Return on invested capital
1.94%
-33.43%
Return on assets
1.4%
-29.94%
Return on equity
4.49%
-40.07%
Earnings Date
Last Earnings Date
Mar
2
Next Earnings Date
May
7
Estimated Next Earnings Date
Jun
1
Balance Sheet
ASTH
Sector
Total cash
$429.5M
$24.9M
Short term investments
$2.4M
$23M
Total assets
$2.2B
$70.1M
Long term debt
$1.1B
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
